Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA consumer warning

This article was originally published in The Tan Sheet

Executive Summary

The dietary supplements Emagrece Sim and Herbathin should not be used and should be returned to suppliers because they "may contain several active ingredients, including controlled substances, found in prescription drugs that could lead to serious side effects or injury," the agency announces Jan. 13. FDA has issued an import alert to prevent importation of the products, which are made in Brazil by the firms Fitoterapicos and Phytotherm Sim. The products contain fluoxetine HCl (Prozac) and chlordiazepoxide HCl (Librium), which are used to relieve anxiety, according to FDA. They also were found to contain Fenproporex, a stimulant that is "not approved for marketing in the U.S." and is converted in the body to amphetamine. The supplements are sold on the Internet, and FDA is "aware of commercial imports of these products and individuals importing them for personal use"...

You may also be interested in...



German CBD Regulation ‘Moving Slowly In The Right Direction’

A recent court case and an upcoming federal election promise movement in Germany's cannbidiol market, stated Joscha Krauss, CEO of local manufacturer MH Medical Hemp GmbH, at the 18th European Industrial Hemp Association (EIHA) Annual Conference.

Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin

Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.

MDR Practicalities: Companies Explain Impact Of Notified Body Timings and Questions Process

Manufacturers initiate an intense communication process when they apply for notified body conformity assessment of their product or quality system. How long does this last, and what impacts its length?

Topics

UsernamePublicRestriction

Register

PS099002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel